Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Takeuchi

Showing results (121-130 of 203) with videos related to

Pageof 21
Sort By:
Journal of Clinical Psychopharmacology|April 22, 2011
Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysisHiroyuki Uchida, Hiroyoshi Takeuchi, Ariel Graff-Guerrero, et al.
The Journal of Clinical Psychiatry|May 3, 2016
Quantifying intraindividual variations in plasma clozapine levels: a population pharmacokinetic approachJimmy Lee, Robert Bies, Hiroyoshi Takeuchi, et al.
Journal of Psychiatric Research|February 12, 2026
Parenting style and deliberate self-harm among children and adolescents: A hospital-based case-control study in JapanYoshikazu Komura, Saiko Ema, Nobuyuki Nomura, et al.
The Journal of Clinical Psychiatry|January 20, 2025
Effects of Intravenous Hydroxyzine Versus Haloperidol Monotherapy for Delirium: A Retrospective StudyKaoruhiko Kubo, Moe Takehara, Mayuko Hirata, et al.
Psychiatry and Clinical Neurosciences|April 8, 2026
Time-dependent risk of falls associated with hypnotic use in hospitalized patientsKazuhiro Shishida, Yutaro Shimomura, Masayuki Murayama, et al.
The Journal of Clinical Psychiatry|February 27, 2014
Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE dataHiroyoshi Takeuchi, Gagan Fervaha, Hiroyuki Uchida, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 6, 2018
Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophreniaHiroyoshi Takeuchi, Cynthia Siu, Gary Remington, et al.
The Journal of Clinical Psychiatry|August 8, 2014
Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled studyHiroyoshi Takeuchi, Takefumi Suzuki, Robert R Bies, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 9, 2015
Antipsychotics and amotivationGagan Fervaha, Hiroyoshi Takeuchi, Jimmy Lee, et al.
Human Psychopharmacology|July 9, 2021
Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithmsHiroyoshi Takeuchi, Yoshiteru Takekita, Hikaru Hori, et al.
Pageof 21

Showing results (121-130 of 203) with videos related to

Sort By:
Pageof 21
Journal of Clinical Psychopharmacology|April 22, 2011
Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysisHiroyuki Uchida, Hiroyoshi Takeuchi, Ariel Graff-Guerrero, et al.
The Journal of Clinical Psychiatry|May 3, 2016
Quantifying intraindividual variations in plasma clozapine levels: a population pharmacokinetic approachJimmy Lee, Robert Bies, Hiroyoshi Takeuchi, et al.
Journal of Psychiatric Research|February 12, 2026
Parenting style and deliberate self-harm among children and adolescents: A hospital-based case-control study in JapanYoshikazu Komura, Saiko Ema, Nobuyuki Nomura, et al.
The Journal of Clinical Psychiatry|January 20, 2025
Effects of Intravenous Hydroxyzine Versus Haloperidol Monotherapy for Delirium: A Retrospective StudyKaoruhiko Kubo, Moe Takehara, Mayuko Hirata, et al.
Psychiatry and Clinical Neurosciences|April 8, 2026
Time-dependent risk of falls associated with hypnotic use in hospitalized patientsKazuhiro Shishida, Yutaro Shimomura, Masayuki Murayama, et al.
The Journal of Clinical Psychiatry|February 27, 2014
Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE dataHiroyoshi Takeuchi, Gagan Fervaha, Hiroyuki Uchida, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 6, 2018
Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophreniaHiroyoshi Takeuchi, Cynthia Siu, Gary Remington, et al.
The Journal of Clinical Psychiatry|August 8, 2014
Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled studyHiroyoshi Takeuchi, Takefumi Suzuki, Robert R Bies, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 9, 2015
Antipsychotics and amotivationGagan Fervaha, Hiroyoshi Takeuchi, Jimmy Lee, et al.
Human Psychopharmacology|July 9, 2021
Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithmsHiroyoshi Takeuchi, Yoshiteru Takekita, Hikaru Hori, et al.
Pageof 21